Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Protectimmun
Düsseldorf, North Rhine-Westphalia, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Protectimmun develops innovative therapies for allergy and chronic inflammation, with its lead program in preclinical phase targeting prophylaxis of allergic asthma. The lead approach is based on transferring protective natural substances found in farming environments to pharmaceutical products, aiming for long-term, stable allergy protection[4][3].
- Therapeutic areas
- Immunology
- Modalities
- Natural substancesMicrobial therapyLive biotherapeutic product therapy
- Industry
- Biotech
02
Partnerships
Janssen Biotech (Johnson & Johnson Innovation)Imperial College London
Beyond the preview
Go deeper on Protectimmun.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protectimmun.